SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Ray Charles

PatientRay Charles
Date of birth1960-09-23
IdentifiersMRN HR-ML009-SYN; SSN (made up) 000-09-5561
Document date2026-06-02
AuthorGloria Fenwick, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month review of recovery, accessibility, and fall prevention. [S]

History of Present Illness

Mr. Charles returns three months after his first visit. He has stayed well while touring. He keeps one naloxone spray at home and one in his travel bag, and the people he travels with have been shown how to use it. He has had no opioid or other drug use and no cravings, including on long tours and in hotel rooms, which he names as the times he is most careful. His eyes have been comfortable. He has had no falls; in hotels he is shown around each new room on arrival and keeps his belongings in fixed places. He has started working on a plan for any future pain with Dr. Fenwick. [S]

ElementDetail
RecoveryNo use and no cravings; aware of travel as a time to be careful
NaloxoneAt home and in his travel bag; travel staff shown how to use it
EyesComfortable
FallsNone; spoken orientation to each new hotel room

Review of Systems

SystemResultFinding
EyesNegativeNo eye pain, redness, or discharge
PsychiatricNegativeMood good; no cravings; no thoughts of suicide or self-harm
MusculoskeletalNegativeNo falls or pain

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrilsOne spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no response, and call 911Nasal route2026-03-03activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-06-02Body height178cmS
2026-06-02Body weight79.8kgS
2026-06-02Body mass index (BMI) [Ratio]25.2kg/m2S
2026-06-02Systolic blood pressure124mm[Hg]S
2026-06-02Diastolic blood pressure78mm[Hg]S
2026-06-02Heart rate68/minS
2026-06-02Respiratory rate14/minS
2026-06-02Body temperature36.7CelS
2026-06-02Oxygen saturation in Arterial blood by Pulse oximetry98%S

Physical Exam

Vital signs recorded on 2026-06-02; see the Vital Signs section. [S]

SystemFinding
GeneralAlert and engaged; each step of the examination described before it was done
EyesNo light perception; lids and ocular surfaces quiet
GaitSteady, walking independently after a spoken orientation to the room
PsychiatricEuthymic; no signs of intoxication or withdrawal

Problems

ProblemClinical statusVerificationCodeProvenance
Blindness of both eyes since childhood, no light perception; cause never diagnosedactiveconfirmed H54.0X55S — Synthetic modern coding of the documented childhood blindness; category 5 (no light perception) is a synthetic grading of what the sources call blindness.
Opioid use disorder (heroin), in sustained remission for more than thirty years, without medication treatmentactiveconfirmed F11.21S — Synthetic modern coding of the publicly admitted heroin addiction and his documented recovery; listed as an active problem because it is managed at every visit, with remission carried by the code.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationEye comfort and ocular surface check: pain, redness, dischargeEvery visitCompleted todayNo pain, redness, or discharge
ExaminationTonometry (eye pressure)Every glaucoma visit; for blind eyes, only if pain or rednessNot indicatedPainless blind eyes, as advised by ophthalmology
ExaminationComprehensive eye examinationYearly for blind eyes, or with symptomsUp to dateOphthalmology examination two months ago
SurveyDepression screen (PHQ-9)At intake, at six months, and yearlyUp to datePHQ-9 2 three months ago; mood good; next at six months
SurveySuicide-risk review and safety plan, with the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline still saved in his phone
Self-managementRecovery check: any return to use, cravings, triggers, and supportsEvery visitCompleted todayNo return to use and no cravings; touring and hotel stays named as times to be careful, with a plan to call a friend if cravings come
Medication safetyNaloxone at home and when travelingAt intake; check expiry at each visitCompleted todayIn date, at home and in his travel bag; travel staff shown how to use it
SurveyDrug-use screen (DAST-10)YearlyUp to dateDAST-10 0 three months ago
SurveyAlcohol screen (AUDIT-C)YearlyUp to dateAUDIT-C 2 three months ago
LaboratoryHepatitis C, hepatitis B, and HIV testingAt entry to care for a person with a substance use disorderDuePlanned for the annual wellness visit, as recorded at the four-week visit
Self-managementWritten plan for any future acute pain or surgeryBefore any planned procedure, and once in remissionDueDrafted today; to be finished at the six-month visit
Self-managementAccessible documents and communicationEvery visitCompleted todayVisit summaries continue as accessible electronic documents
Medication safetyMedicine labeling in braille or audioWith every new prescriptionUp to dateNo new prescriptions
ExaminationCDC STEADI fall-risk screenEvery visit from age 65Completed todayNo falls; steady gait
Self-managementAdvance care planningYearly from age 65DueAt the annual wellness visit

Goal progress:

Guideline basis: VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Primary Open-Angle Glaucoma Preferred Practice Pattern (2025); Vision Rehabilitation Preferred Practice Pattern (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, glaucoma and depression, bipolar, and mood disorders monographs (2026)

Follow-up: Six-month review with the PHQ-9 and the finished pain plan. Next scheduled visit 2026-09-01: six-month review with depression screening and a plan for any future pain. [S]